Literature DB >> 6608501

Immune complexes in ovarian cancer: association between IgM class complexes and antinuclear autoantibodies in ascitic fluid.

P A Silburn, J C Neil, S K Khoo, B Daunter, R Hill, R J Collins, E V Mackay.   

Abstract

Samples of ascitic fluid from patients with ovarian cancer were analyzed for autoantibodies to nuclear and cytoplasmic antigens and for immune complexes (ICs) detectable by the Clq deviation and polyethylene glycol (PEG) precipitation (either IgG or IgM class) assays. The predominant autoantibody was antinuclear (ANA); this was detected in 29 of 58 samples (59% showing the homogeneous and 41% the speckled pattern). The antibody was not reactive to saline extractable nuclear antigens. A strong association between this autoantibody and the PEG-precipitated IgM class ICs was shown, suggesting the possible participation of this autoantibody in IgM class ICs formation. The lack of association between C1q-reactive and IgG class ICs and the autoantibodies indicates that the IgG class ICs may be more related to the tumor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608501     DOI: 10.1159/000233517

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases.

Authors:  Lucinda Aguirre-Cruz; Jean-Luc Charuel; Antoine F Carpentier; Baya Benyahia; Jean-Yves Delattre; Lucile Musset
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].

Authors:  M J Behne; U Hauswirth; A Menz; N Brüllke; U Müllerleile; I Moll
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

3.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.